Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.48 |
| ▸ | RXRB | P28702 | 8/20 | 0.48 |
| ▸ | RXRG | P48443 | 6/20 | 0.48 |
| ▸ | RARB | P10826 | 10/20 | 0.47 |
| ▸ | RARA | P10276 | 8/20 | 0.47 |
| ▸ | RARG | P13631 | 8/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.44 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292641 | 0.89 | RXRA (0.52) | RXRARXRBRXRGRARBRARA | |
| SCHEMBL6294271 | 0.87 | RXRA (0.49) | RXRARXRBRXRGRARBRARA | |
| SCHEMBL6294155 | 0.83 | RARA (0.49) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL6297298 | 0.81 | RXRA (0.46) | RXRARXRBRXRGRARBRARA | |
| SCHEMBL6292968 | 0.80 | RARB (0.62) | RXRARXRBRXRGRARBRARA | |
| SCHEMBL6292438 | 0.80 | RXRA (0.40) | RXRARXRBRXRGRARBRARA | |
| SCHEMBL9165893 | 0.79 | RXRA (0.69) | RXRARXRBRXRGRARBRARA | |
| SCHEMBL6294100 | 0.79 | RXRA (0.47) | RXRARXRBRXRGRARBRARA | |
| SCHEMBL6292635 | 0.76 | RARA (0.62) | RARBRARARARGCYP3A4 | |
| SCHEMBL12620654 | 0.75 | RARB (0.38) | RXRARXRBRXRGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555690-B2 | 4-((5,5-dimethyl-5,6,7,8-tetrahydro-8-hydroxynaphthalen-2 -yl)carbonyloxy)benzoic acid, benzyl ester for example; receptor subtype selectivity for side effect reduction | ALLERGAN, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20020173631-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173631-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RXRA 4/4885RXRB 3/4885RXRG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.